<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173533</url>
  </required_header>
  <id_info>
    <org_study_id>RG_18-048</org_study_id>
    <nct_id>NCT04173533</nct_id>
  </id_info>
  <brief_title>Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT</brief_title>
  <acronym>AMADEUS</acronym>
  <official_title>A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate a new maintenance therapy with the aim of improving the outcome of&#xD;
      patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, two arm, double-blind, phase III clinical trial in adult patients with&#xD;
      acute myeloid leukaemia (AML) and myelodisplasia (MDS) who have undergone an allogeneic stem&#xD;
      cell transplant (allo-SCT) and are randomised to receive oral azacitidine or placebo upon&#xD;
      engraftment for up to 12 months as maintenance therapy. Patients will be stratified by type&#xD;
      of transplant (myeloablative/reduced intensity, age (&lt;60/≥ 60 years) and donor type&#xD;
      (sibling/unrelated)).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse free survival (RFS)</measure>
    <time_frame>12 months</time_frame>
    <description>To determine RFS at one year from randomisation of oral azacitidine compared with placebo in patients undergoing allo-SCT for AML/MDS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>OS at one and two years from randomisation of oral azacitidine compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>CIR at one and two years after treatment comparing oral azacitidine with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>Day 100 and 12 months</time_frame>
    <description>NRM at 100 days and 12 months after treatment comparing oral azacitidine with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GVHD</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of acute and chronic GVHD comparing oral azacitidine with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to early treatment discontinuation</measure>
    <time_frame>24 months</time_frame>
    <description>Time to early treatment discontinuation compairing oral azacitidine with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with adverse events on oral azacitidine compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EORTC-QLQ-C30 and EQ-5D)</measure>
    <time_frame>24 months</time_frame>
    <description>QoL will be measured to compare oral azacitidine with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free and relapse-free survival (GRFS)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>GRFS defined as time from date of randomisation to date of first event or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral azacitidine (CC-486) matched placebo once daily for first 14 days of each 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral azacitidine (CC-486) 200 mg once daily for first 14 days of each 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral azacitidine</intervention_name>
    <description>Oral azacitidine (CC-486) 200 mg tablet</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>CC-486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched placebo</intervention_name>
    <description>Oral azacitidine (CC-486) matched placebo tablet</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Oral azacitidine matched placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 16 at the time of signing the informed consent form&#xD;
&#xD;
          2. Patients with a diagnosis of AML (CR1 or CR2) according to WHO classification or high&#xD;
             risk MDS (as per IPSS-R) undergoing allo-SCT using MAC or RIC preparative regimens,&#xD;
             and with either peripheral blood or bone marrow as the source of hematopoietic stem&#xD;
             cells.&#xD;
&#xD;
          3. At the time of allo-SCT&#xD;
&#xD;
               -  No prior allo-SCT; and&#xD;
&#xD;
               -  No more than 1 antigen mismatch at HLA-A, -B, -C, -DRB1 or -DQB1 locus for either&#xD;
                  related or unrelated donor; and&#xD;
&#xD;
               -  No haplotype or cord blood donor; and&#xD;
&#xD;
               -  Bone marrow blast &lt;5% for AML and &lt;10% for MDS patients&#xD;
&#xD;
          4. Able to commence therapy between 42 to 84 days following allo-SCT&#xD;
&#xD;
          5. Post-transplant bone marrow&#xD;
&#xD;
               1. AML patients - blast count ≤ 5% confirmed within 28 days prior to starting study&#xD;
                  therapy&#xD;
&#xD;
               2. MDS patients - confirmation of CR post-transplant with blast count ≤ 5% in bone&#xD;
                  marrow&#xD;
&#xD;
          6. Adequate neutrophil and platelet engraftment within 14 days prior to starting study&#xD;
             therapy defined as:&#xD;
&#xD;
               -  ANC ≥ 1.0 x 10^9/L on two consecutive testing without daily use of myeloid growth&#xD;
                  factor; and&#xD;
&#xD;
               -  Platelet ≥ 50 x 10^9/L on two consecutive testing without platelet transfusion&#xD;
                  within 1 week&#xD;
&#xD;
          7. Adequate organ function:&#xD;
&#xD;
               -  Serum AST and ALT &lt; 4 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum bilirubin &lt; 2 x ULN. Higher levels are acceptable if these can be&#xD;
                  attributed to active red blood cell (RBC) precursor destruction within the bone&#xD;
                  marrow (i.e., ineffective erythropoiesis) or Gilbert's syndrome&#xD;
&#xD;
               -  Serum creatinine &lt; 2 x ULN&#xD;
&#xD;
          8. Adequate coagulation (PT ≤ 15 seconds and PTT ≤ 40 seconds)&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2&#xD;
&#xD;
         10. Patients with adequately controlled GVHD (defined as GVHD grade &lt;II with concurrent&#xD;
             use of corticosteroids equivalent of prednisone at a dose ≤ 0.5 mg/kg) can be included&#xD;
&#xD;
         11. Females of childbearing potential (FCBP) may participate, providing they meet the&#xD;
             following conditions:&#xD;
&#xD;
               1. Agree to use at least two effective contraceptive methods (oral, injectable, or&#xD;
                  implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier&#xD;
                  contraceptive with spermicide; or vasectomised partner) or practice true&#xD;
                  abstinence throughout the study, and for 3 months following the last dose of&#xD;
                  study therapy and&#xD;
&#xD;
               2. Have a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at&#xD;
                  screening; and&#xD;
&#xD;
               3. Have a negative serum or urine (investigator's discretion) pregnancy test&#xD;
                  (sensitivity of at least 25 mIU/mL) within 72 hours prior to starting study&#xD;
                  therapy. This applies even if the subject practices complete abstinence from&#xD;
                  heterosexual contact.&#xD;
&#xD;
         12. Male patients with a female partner of childbearing potential must agree to the use of&#xD;
             at least two physician-approved contraceptive methods throughout the course of the&#xD;
             study and should avoid fathering a child during the course of the study and for 3&#xD;
             months following the last dose study therapy&#xD;
&#xD;
         13. Understand and voluntarily sign an informed consent from prior to any study related&#xD;
             assessments or procedures being conducted&#xD;
&#xD;
         14. Able to adhere to the study visit schedule (i.e., clinic visits at the study sites are&#xD;
             mandatory, unless noted otherwise for study visits) and other protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any of the following after transplantation and prior to starting study therapy:&#xD;
&#xD;
               -  Any agents (chemotherapy or targeted agents) used for adjuvant therapy (note that&#xD;
                  prophylactic use of these agents is allowed in this study, e.g., methotrexate for&#xD;
                  GVHD or rituximab for Epstein-Barr Virus (EBV) reactivation)&#xD;
&#xD;
               -  Unlicensed investigational agents/therapies used within 28 days prior to starting&#xD;
                  study therapy&#xD;
&#xD;
               -  Azacitidine, decitabine or other hypomethylating agent (HMA)&#xD;
&#xD;
               -  Lenalidomide, thalidomide and pomalidomide used within 28 days prior to starting&#xD;
                  study therapy&#xD;
&#xD;
          2. Subjects who have undergone a haploidentical or cord blood transplant&#xD;
&#xD;
          3. Active GVHD grade II or higher (acute GVHD Clinical Staging and Grading)&#xD;
&#xD;
          4. Concurrent use of corticosteroids equivalent of prednisone at a dose &gt; 0.5 mg/kg&#xD;
&#xD;
          5. Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B&#xD;
             Virus (HBV) or Hepatitis C Virus (HCV)&#xD;
&#xD;
          6. Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing&#xD;
             signs/symptoms related to the infection without improvement despite appropriate&#xD;
             antibiotics, antiviral therapy, and/or other treatment)&#xD;
&#xD;
          7. History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis),&#xD;
             celiac disease (i.e., sprue), prior gastrectomy or upper bowel removal, or any other&#xD;
             GI disorder or defect that may interfere with the absorption, distribution, metabolism&#xD;
             or excretion of the investigational medicinal products (IMPs) and/or predispose the&#xD;
             subject to an increased risk of gastrointestinal toxicity prior to allo-SCT&#xD;
&#xD;
          8. Idiopathic thrombocytopenic purpura (ITP), disseminated intravascular coagulation,&#xD;
             haemolytic uremic syndrome, thrombotic thrombocytopenic purpura (TTP)&#xD;
&#xD;
          9. History of prior malignancies, except lobular breast carcinoma in situ, fully resected&#xD;
             basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ,&#xD;
             Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node,&#xD;
             metastasis (TNM) clinical staging system), CMML or Secondary AML arising from MDS.&#xD;
             Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer&#xD;
             treated with curative intent &lt; 5 years previously will not be allowed.&#xD;
&#xD;
         10. Significant active cardiac disease within the previous 6 months, including:&#xD;
&#xD;
               -  New York Heart Association (NYHA) class III or IV congestive heart failure&#xD;
&#xD;
               -  Unstable angina or angina requiring surgical or medical intervention; and/or&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
         11. Known or suspected hypersensitivity to azacitidine or mannitol&#xD;
&#xD;
         12. Pregnant or lactating females&#xD;
&#xD;
         13. Any significant medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the patient from participating in the study.&#xD;
&#xD;
         14. Any condition including the presence of laboratory abnormalities, which places the&#xD;
             patient at unacceptable risk if he/she were to participate in the study&#xD;
&#xD;
         15. Any condition that confounds the ability to interpret data from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Craddock</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eszter Nagy</last_name>
    <phone>00442123717858</phone>
    <email>amadeus@trials.bham.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emmanuel Nikolousis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Craddock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bristol</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachel Protheroe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Charles Crawley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wendy Ingram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne-Louise Latif</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Gilleece</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ann Hunter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Arpad Toth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiri Pavlu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victoria Potter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeff Davies</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emma Nicholson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Panagiotis Kottaridis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muhammad Saif</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mike Dennis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erin Hurst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jenny Byrne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andy Peniket</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hannah Hunter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Harpreet Kaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

